FDA PUBLIC REVIEW OF OTC ANALGESIC INDICATIONS
This article was originally published in The Tan Sheet
Executive Summary
FDA PUBLIC REVIEW OF OTC ANALGESIC INDICATIONS will take place "hopefully...this year," Office of OTC Drug Evaluation Director Michael Weintraub, MD, told the Senate Appropriations/agriculture subcommittee at a May 10 hearing on FDA's fiscal 1995 budget. In response to a series of questions regarding FDA's Rx-to-OTC switch review process from Sen. Thad Cochran (R-Miss.), Weintraub said the OTC office has "set up hopefully for later this year a larger open committee meeting with all sorts of experts in the field of pain and...what we call analgesiology."